Cargando…
Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease
INTRODUCTION: Graves’ disease (GD) is an autoimmune disorder caused by autoantibodies against the thyroid stimulating hormone receptor (TSHR) leading to overstimulation of the thyroid gland. Thyroid eye disease (TED) is the most common extra thyroidal manifestation of GD. Therapeutic options to trea...
Autores principales: | Gulbins, Anne, Horstmann, Mareike, Daser, Anke, Flögel, Ulrich, Oeverhaus, Michael, Bechrakis, Nikolaos E., Banga, J. Paul, Keitsch, Simone, Wilker, Barbara, Krause, Gerd, Hammer, Gary D., Spencer, Andrew G., Zeidan, Ryan, Eckstein, Anja, Philipp, Svenja, Görtz, Gina-Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10331459/ https://www.ncbi.nlm.nih.gov/pubmed/37435490 http://dx.doi.org/10.3389/fendo.2023.1211473 |
Ejemplares similares
-
OR26-03 Treatment With Linsitinib, An IGF-1 Receptor Inhibitor, Prevents Disease Development And Progression In An Experimental Model Of Thyroid Eye Disease
por: Gulbins, Anne, et al.
Publicado: (2023) -
Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease
por: Gulbins, Anne, et al.
Publicado: (2023) -
Graves’ orbitopathy occurs sex-independently in an autoimmune hyperthyroid mouse model
por: Schlüter, Anke, et al.
Publicado: (2018) -
Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis
por: Oeverhaus, Michael, et al.
Publicado: (2023) -
Novel Insights into Pathophysiology of Orbital Inflammatory Diseases and Progression to Orbital Lymphoma by Pathway Enrichment Analysis
por: Al-Ghazzawi, Karim, et al.
Publicado: (2022)